Khurram Jamil - 02 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
02 Jan 2026
Net transactions value
-$232,402
Form type
4
Filing time
06 Jan 2026, 16:53:32 UTC
Previous filing
05 Jan 2026
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jamil Khurram Chief Medical Officer 4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS Jack W. Callicutt, by power of attorney 06 Jan 2026 0002032345

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Options Exercise $0 +60,000 $0.000000 60,000 02 Jan 2026 Direct F3
transaction GALT Common Stock Sale $54,789 -13,055 -22% $4.20 46,945 02 Jan 2026 Direct F1, F2
transaction GALT Common stock Sale $99,408 -25,499 -54% $3.90 21,446 05 Jan 2026 Direct F1, F5
transaction GALT Common Stock Sale $78,205 -21,446 -100% $3.65 0 06 Jan 2026 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Restricted Stock Unit Options Exercise $0 -60,000 -100% $0.000000 0 01 Jan 2026 Common Stock 60,000 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.
F2 The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units.
F4 Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026.
F5 The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F6 The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.